Processa (NASDAQ: PCSA) CEO adds 1,843 shares in open-market buy

Rhea-AI Filing Summary

Processa Pharmaceuticals, Inc. Chief Executive Officer George K. Ng reported an open-market purchase of common stock. On April 15, 2026, he bought 1,843 shares of Processa common stock at $2.97 per share, bringing his directly held stake to 3,979 shares.

The filing also shows indirect holdings of 800 shares held through the Ng Cha Family Trust and 3,488 shares held through an account identified as George Ng IRRA FOB George Ng. These lines reflect ownership positions rather than new transactions.

Insider Trade Summary

Net Buyer: 1,843 shares ($5,474)

Net Buy 3 txns

Insider Ng George K

Role Chief Executive Officer

Bought 1,843 shs ($5K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	1,843	$2.97	$5K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 3,979 shares (Direct, null); Common Stock — 3,488 shares (Indirect, George Ng IRRA FOB George Ng)

Footnotes (1)

Key Figures

Shares purchased: 1,843 shares Purchase price: $2.97 per share Direct holdings after transaction: 3,979 shares +3 more

6 metrics

Shares purchased 1,843 shares Open-market purchase of common stock on April 15, 2026

Purchase price $2.97 per share Price paid for 1,843 purchased shares

Direct holdings after transaction 3,979 shares Common stock directly owned by George K. Ng after purchase

Indirect holdings - Ng Cha Family Trust 800 shares Common stock held indirectly via Ng Cha Family Trust

Indirect holdings - IRRA account 3,488 shares Common stock held indirectly via George Ng IRRA FOB George Ng

Net buy shares 1,843 shares Net change in buy/sell activity in this filing

Key Terms

open-market purchase, indirect ownership, Form 4/A, common stock

4 terms

open-market purchase financial

"transaction_action is described as an open-market purchase of common stock"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

indirect ownership financial

"entries list indirect ownership through Ng Cha Family Trust and IRRA account"

Form 4/A regulatory

"the insider transaction is reported on an amended Form 4/A"

Form 4/A is an amended filing that corrects or updates an earlier Form 4, the mandatory report that insiders (like company executives, directors, or large shareholders) must file when their ownership stakes change. Think of it as an edited receipt showing who bought or sold stock and when; investors use it to track insider confidence, detect potential conflicts, and spot trading patterns that might signal future company prospects.

common stock financial

"all reported holdings and the purchase involve Processa common stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ng George K

(Last) (First) (Middle)

C/O PROCESSA PHARMACEUTICALS, INC.

601 21ST STREET SUITE 300

(Street)

VERO BEACH FLORIDA 32960

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Processa Pharmaceuticals, Inc. [ PCSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
04/17/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/15/2026		P		1,843	A	$2.97	3,979	D
Common Stock								3,488	I	George Ng IRRA FOB George Ng
Common Stock								800	I	Ng Cha Family Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ George Ng, by John J. Wolfel, as Attorney-in-Fact	04/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did PCSA CEO George Ng report on this Form 4/A?

George K. Ng reported an open-market purchase of Processa Pharmaceuticals common stock. He bought 1,843 shares on April 15, 2026 at $2.97 per share, increasing his directly held stake to 3,979 shares after the transaction.

How many PCSA shares does George Ng own directly after this transaction?

After the reported purchase, George K. Ng directly owns 3,979 shares of Processa Pharmaceuticals common stock. This figure reflects his direct holdings only and is separate from additional shares reported as indirectly owned through trust and retirement-related accounts.

Were there any indirect PCSA share holdings disclosed for George Ng?

Yes. The filing lists 800 shares of Processa common stock held indirectly through the Ng Cha Family Trust and 3,488 shares held indirectly through an account labeled George Ng IRRA FOB George Ng, in addition to his direct holdings.

What price did PCSA CEO George Ng pay per share in the reported purchase?

George K. Ng paid $2.97 per share for the 1,843 shares of Processa Pharmaceuticals common stock he bought on April 15, 2026. This price reflects the transaction value reported for that specific open-market purchase.

Does this PCSA Form 4/A filing report any stock sales by George Ng?

No stock sales are reported. The Form 4/A shows an open-market purchase of 1,843 shares by George K. Ng and two entries reflecting indirect holdings, which represent ownership positions rather than sale or disposition transactions.

What is the overall net share change for PCSA CEO George Ng in this Form 4/A?

The filing reflects a net buy of 1,843 shares of Processa Pharmaceuticals common stock. This comes from a single open-market purchase transaction, with no reported stock sales or derivative exercises in the disclosed data.